Shuaizhen Zhou1,2, Pierre-Marie Allard1, Christian Wolfrum3, Changqiang Ke2, Chunping Tang2, Yang Ye4, Jean-Luc Wolfender5. 1. School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne, CMU - Rue Michel-Servet 1, CH-1206, Geneva 4, Switzerland. 2. State Key Laboratory of Drug Research, & SIMM/CUHK Joint Research Laboratory of Promoting of Traditional Chinese Medicines, Natural Products Chemistry Department, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu-Chong-Zhi Road, Zhangjiang High-Tech Park, Shanghai, 201203, People's Republic of China. 3. Swiss Federal Institute of Technology, ETH Zürich, Institute of Food Nutrition and Health, Schorenstr. 16, 8603, Schwerzenbach, Switzerland. 4. State Key Laboratory of Drug Research, & SIMM/CUHK Joint Research Laboratory of Promoting of Traditional Chinese Medicines, Natural Products Chemistry Department, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu-Chong-Zhi Road, Zhangjiang High-Tech Park, Shanghai, 201203, People's Republic of China. yye@simm.ac.cn. 5. School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne, CMU - Rue Michel-Servet 1, CH-1206, Geneva 4, Switzerland. Jean-Luc.Wolfender@unige.ch.
Abstract
INTRODUCTION: Bitter melon (Momordica charantia, Cucurbitaceae) is a popular edible medicinal plant, which has been used as a botanical dietary supplement for the treatment of diabetes and obesity in Chinese folk medicine. Previously, our team has proved that cucurbitanes triterpenoid were involved in bitter melon's anti-diabetic effects as well as on increasing energy expenditure. The triterpenoids composition can however be influenced by changes of varieties or habitats. OBJECTIVES: To clarify the significance of bioactive metabolites diversity among different bitter melons and to provide a guideline for selection of bitter melon varieties, an exploratory study was carried out using a UHPLC-HRMS based metabolomic study to identify chemotypes. METHODS: Metabolites of 55 seed samples of bitter melon collected in different parts of China were profiled by UHPLC-HRMS. The profiling data were analysed with multivariate (MVA) statistical methods. Principle component analysis (PCA) and hierarchical cluster analysis (HCA) were applied for sample differentiation. Marker compounds were identified by comparing spectroscopic data with isolated compounds, and additional triterpenes were putatively identified by propagating annotations through a molecular network (MN) generated from UHPLC-HRMS & MS/MS metabolite profiling. RESULTS: PCA and HCA provided a good discrimination between bitter melon samples from various origins in China. This study revealed for the first time the existence of two chemotypes of bitter melon. Marker compounds of those two chemotypes were identified at different MSI levels. The combined results of MN and MVA demonstrated that the two chemotypes mainly differ in their richness in cucurbitane versus oleanane triterpenoid glycosides (CTGs vs. OTGs). CONCLUSION: Our finding revealed a clear chemotype distribution of bioactive components across bitter melon varieties. While bioactivities of individual CTGs and OTGs still need to be investigated in more depth, our results could help in future the selection of bitter melon varieties with optimised metabolites profile for an improved management of diabetes with this popular edible Chinese folk medicine.
INTRODUCTION:Bitter melon (Momordica charantia, Cucurbitaceae) is a popular edible medicinal plant, which has been used as a botanical dietary supplement for the treatment of diabetes and obesity in Chinese folk medicine. Previously, our team has proved that cucurbitanes triterpenoid were involved in bitter melon's anti-diabetic effects as well as on increasing energy expenditure. The triterpenoids composition can however be influenced by changes of varieties or habitats. OBJECTIVES: To clarify the significance of bioactive metabolites diversity among different bitter melons and to provide a guideline for selection of bitter melon varieties, an exploratory study was carried out using a UHPLC-HRMS based metabolomic study to identify chemotypes. METHODS: Metabolites of 55 seed samples of bitter melon collected in different parts of China were profiled by UHPLC-HRMS. The profiling data were analysed with multivariate (MVA) statistical methods. Principle component analysis (PCA) and hierarchical cluster analysis (HCA) were applied for sample differentiation. Marker compounds were identified by comparing spectroscopic data with isolated compounds, and additional triterpenes were putatively identified by propagating annotations through a molecular network (MN) generated from UHPLC-HRMS & MS/MS metabolite profiling. RESULTS: PCA and HCA provided a good discrimination between bitter melon samples from various origins in China. This study revealed for the first time the existence of two chemotypes of bitter melon. Marker compounds of those two chemotypes were identified at different MSI levels. The combined results of MN and MVA demonstrated that the two chemotypes mainly differ in their richness in cucurbitane versus oleananetriterpenoid glycosides (CTGs vs. OTGs). CONCLUSION: Our finding revealed a clear chemotype distribution of bioactive components across bitter melon varieties. While bioactivities of individual CTGs and OTGs still need to be investigated in more depth, our results could help in future the selection of bitter melon varieties with optimised metabolites profile for an improved management of diabetes with this popular edible Chinese folk medicine.
Authors: H Shibuya; K Kawashima; M Sakagami; H Kawanishi; M Shimomura; K Ohashi; I Kitagawa Journal: Chem Pharm Bull (Tokyo) Date: 1990-11 Impact factor: 1.645
Authors: Amy C Keller; Jun Ma; Adam Kavalier; Kan He; Anne-Marie B Brillantes; Edward J Kennelly Journal: Phytomedicine Date: 2011-11-30 Impact factor: 5.340
Authors: Samuel Kaiser; Ânderson Ramos Carvalho; Vanessa Pittol; Fabrícia Dietrich; Fabiana Manica; Michel Mansur Machado; Luis Flávio Souza de Oliveira; Ana Maria Oliveira Battastini; George González Ortega Journal: J Ethnopharmacol Date: 2016-05-13 Impact factor: 4.360
Authors: Lloyd W Sumner; Alexander Amberg; Dave Barrett; Michael H Beale; Richard Beger; Clare A Daykin; Teresa W-M Fan; Oliver Fiehn; Royston Goodacre; Julian L Griffin; Thomas Hankemeier; Nigel Hardy; James Harnly; Richard Higashi; Joachim Kopka; Andrew N Lane; John C Lindon; Philip Marriott; Andrew W Nicholls; Michael D Reily; John J Thaden; Mark R Viant Journal: Metabolomics Date: 2007-09 Impact factor: 4.290